Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

VISION-DMD

- PMLiVE

Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...

Uniphar

- PMLiVE

Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy

The muscle-wasting disorder is estimated to affect one in every 5,000 male births worldwide

- PMLiVE

Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC

The rare muscle-wasting disorder affects approximately 2,500 males in the UK at any one time

- PMLiVE

MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy

The severe neuromuscular disease affects approximately 2,500 people in the UK

- PMLiVE

NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

- PMLiVE

FDA expands indication for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys

The neuromuscular condition is estimated to affect one in every 3,500 male births worldwide

- PMLiVE

FDA approves Italfarmaco’s Duvyzat as first nonsteroidal Duchenne muscular dystrophy drug

The neuromuscular genetic disease is estimated to affect one in every 3,500 to 6,000 male births worldwide

- PMLiVE

Santhera’s Duchenne muscular dystrophy drug shows promise as long-term treatment

The muscle-wasting disorder is estimated to affect one in every 3,500 male births worldwide

- PMLiVE

MHRA approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

- PMLiVE

EC approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

- PMLiVE

FDA approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

- PMLiVE

EMA endorses digital measure as primary endpoint in Duchenne muscular dystrophy trials

The decision qualifies SV95C as an alternative to the widely used six-minute walking test

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links